In Vivo CD19/CD20 CAR T-Cell Therapy Is Safe, Yields 100% ORR at Phase 1, Dose Level 2 in R/R Non-Hodgkin Lymphomas - OncLive
In Vivo CD19/CD20 CAR T-Cell Therapy Is Safe, Yields 100% ORR at Phase 1, Dose Level 2 in R/R Non-Hodgkin Lymphomas OncLive
Non-Hodgkin Lymphoma News
Diffuse Large B-Cell Lymphoma Masquerading as Recurrent Pleural Effusion and Melena: A Case Report and Literature Review - Cureus
Diffuse Large B-Cell Lymphoma Masquerading as Recurrent Pleural Effusion and Melena: A Case Report and Literature Review Cureus
Andy Whitfield’s Final Battle: The Spartacus Star and Stage IV Non-Hodgkin Lymphoma - Oncodaily
Andy Whitfield’s Final Battle: The Spartacus Star and Stage IV Non-Hodgkin Lymphoma Oncodaily
Non-Hodgkin lymphoma: inpatient TLS is uncommon but predictable from high–tumor burden and early lab derangements - Vera Health
Non-Hodgkin lymphoma: inpatient TLS is uncommon but predictable from high–tumor burden and early lab derangements Vera Health
Legend Biotech Establishes Clinical Proof-of-Concept for - GlobeNewswire
Legend Biotech Establishes Clinical Proof-of-Concept for GlobeNewswire
FDA Accepts Supplemental Biologics License Application for Genentech’s Lunsumio and Polivy Combination for People With Relapsed or Refractory Large B-Cell Lymphoma - Business Wire
FDA Accepts Supplemental Biologics License Application for Genentech’s Lunsumio and Polivy Combination for People With Relapsed or Refractory Large B-Cell Lymphoma Business Wire
Non-Hodgkin lymphoma survivor thankful for clinical trial - UT MD Anderson
Non-Hodgkin lymphoma survivor thankful for clinical trial UT MD Anderson
Single-dose lymphoma CAR-T from Legend Biotech hits 100% response at top dose - Stock Titan
Single-dose lymphoma CAR-T from Legend Biotech hits 100% response at top dose Stock Titan
Study reveals promising new therapy for non-Hodgkin lymphoma - Medical Xpress
Study reveals promising new therapy for non-Hodgkin lymphoma Medical Xpress
FDA Orphan Drug Status Awarded to EO2463 in Indolent Non-Hodgkin Lymphoma - Targeted Oncology
FDA Orphan Drug Status Awarded to EO2463 in Indolent Non-Hodgkin Lymphoma Targeted Oncology
Soligenix axes lymphoma program after phase 3 setback, mulls M&A options - Fierce Biotech
Soligenix axes lymphoma program after phase 3 setback, mulls M&A options Fierce Biotech
New long-term analysis suggests follicular lymphoma can be cured - Fred Hutchinson Cancer Center
New long-term analysis suggests follicular lymphoma can be cured Fred Hutchinson Cancer Center
Report: Counties that spray the most glyphosate have higher non-Hodgkin lymphoma rates - Iowa Capital Dispatch
Report: Counties that spray the most glyphosate have higher non-Hodgkin lymphoma rates Iowa Capital Dispatch
Rethinking Dual Targeting, Durability After CAR-T in Non-Hodgkin Lymphoma - CancerNetwork
Rethinking Dual Targeting, Durability After CAR-T in Non-Hodgkin Lymphoma CancerNetwork
Primary Bone Diffuse Large B-cell Lymphoma (DLBCL) in a Young Adult: A Case Report - Cureus
Primary Bone Diffuse Large B-cell Lymphoma (DLBCL) in a Young Adult: A Case Report Cureus
FDA accepts supplemental Biologics License Application for - GlobeNewswire
FDA accepts supplemental Biologics License Application for GlobeNewswire
Stage IV non-Hodgkin lymphoma survivor: Why I’m excited about UT MD Anderson coming to Austin - UT MD Anderson
Stage IV non-Hodgkin lymphoma survivor: Why I’m excited about UT MD Anderson coming to Austin UT MD Anderson
The Evolving Roles of MRD and Molecular Genotyping in Non-Hodgkin Lymphoma - CancerNetwork
The Evolving Roles of MRD and Molecular Genotyping in Non-Hodgkin Lymphoma CancerNetwork
Long-term follow-up demonstrates the curative potential of dual CD19/CD22 CAR-T-cell therapy alone or combined with autologous stem cell transplantation in TP53-altered relapsed/refractory B-cell non-Hodgkin lymphoma | Signal Transduction and Targete - Nature
Long-term follow-up demonstrates the curative potential of dual CD19/CD22 CAR-T-cell therapy alone or combined with autologous stem cell transplantation in TP53-altered relapsed/refractory B-cell non-Hodgkin lymphoma | Signal Transduction and Targete Nature
Non-Hodgkin Lymphoma Treatment Market Size, Forecast, 2034 - Fortune Business Insights
Non-Hodgkin Lymphoma Treatment Market Size, Forecast, 2034 Fortune Business Insights
Legend Biotech (NASDAQ: LEGN) unveils promising first-in-human LB2501 in vivo CAR-T results - Stock Titan
Legend Biotech (NASDAQ: LEGN) unveils promising first-in-human LB2501 in vivo CAR-T results Stock Titan
Roundup Non-Hodgkin’s Lymphoma Lawsuit [2026 Update] - robertkinglawfirm.com
Roundup Non-Hodgkin’s Lymphoma Lawsuit [2026 Update] robertkinglawfirm.com
Miami F Marcus Allen has non-Hodgkin lymphoma, out for season - ESPN
Miami F Marcus Allen has non-Hodgkin lymphoma, out for season ESPN
T-Cell Therapy EB103 Demonstrates Safety in B-Cell Non-Hodgkin Lymphoma - Targeted Oncology
T-Cell Therapy EB103 Demonstrates Safety in B-Cell Non-Hodgkin Lymphoma Targeted Oncology
Enterome presents Phase 2 indolent non-Hodgkin lymphoma - GlobeNewswire
Enterome presents Phase 2 indolent non-Hodgkin lymphoma GlobeNewswire
Non-Hodgkin’s lymphoma presenting as a retroperitoneal mass in the emergency department: a case report - Frontiers
Non-Hodgkin’s lymphoma presenting as a retroperitoneal mass in the emergency department: a case report Frontiers
Levofloxacin for the prevention of febrile episodes in non-Hodgkin lymphoma patients treated with CHOP plus rituximab in a randomized controlled trial - Nature
Levofloxacin for the prevention of febrile episodes in non-Hodgkin lymphoma patients treated with CHOP plus rituximab in a randomized controlled trial Nature
Case Report: A case of jejunal T-cell non-Hodgkin lymphoma with secondary bone involvement presenting as gastrointestinal perforation - Frontiers
Case Report: A case of jejunal T-cell non-Hodgkin lymphoma with secondary bone involvement presenting as gastrointestinal perforation Frontiers
Lymphocyte Kinetics After CAR T-Cell Infusion May Predict Survival Outcomes in Non-Hodgkin Lymphoma - The ASCO Post
Lymphocyte Kinetics After CAR T-Cell Infusion May Predict Survival Outcomes in Non-Hodgkin Lymphoma The ASCO Post
5-Year Follow-Up From AUGMENT Lenalidomide Plus Rituximab in Relapsed or Refractory Indolent Non-Hodgkin Lymphoma - The ASCO Post
5-Year Follow-Up From AUGMENT Lenalidomide Plus Rituximab in Relapsed or Refractory Indolent Non-Hodgkin Lymphoma The ASCO Post
CAR T-Cell Therapy for Non-Hodgkin’s Lymphoma Market Expected to Witness Significant Expansion Through 2034, According to DelveInsight - Barchart.com
CAR T-Cell Therapy for Non-Hodgkin’s Lymphoma Market Expected to Witness Significant Expansion Through 2034, According to DelveInsight Barchart.com
Axi-Cel Shows Durable Responses, Curative Hope in Non-Hodgkin Lymphoma - Targeted Oncology
Axi-Cel Shows Durable Responses, Curative Hope in Non-Hodgkin Lymphoma Targeted Oncology
Targeting CAR-T cell exhaustion in non-Hodgkin lymphoma: mechanistic insights and emerging clinical strategies - Frontiers
Targeting CAR-T cell exhaustion in non-Hodgkin lymphoma: mechanistic insights and emerging clinical strategies Frontiers
Hepatitis virus-associated B cell non-Hodgkin’s lymphoma involves dysregulated epigenetic and RNA-mediated regulatory gene expression and altered snoRNA transcription - Nature
Hepatitis virus-associated B cell non-Hodgkin’s lymphoma involves dysregulated epigenetic and RNA-mediated regulatory gene expression and altered snoRNA transcription Nature
Pharmacokinetics of Odronextamab, A Bispecific T‐Cell‐Engaging Antibody, in Adult Patients With Relapsed or Refractory B‐Cell Non‐Hodgkin Lymphoma - Bravo Padros - 2026 - CPT: Pharmacometrics & Systems Pharmacology - Wiley Online Library - Wiley
Pharmacokinetics of Odronextamab, A Bispecific T‐Cell‐Engaging Antibody, in Adult Patients With Relapsed or Refractory B‐Cell Non‐Hodgkin Lymphoma - Bravo Padros - 2026 - CPT: Pharmacometrics & Systems Pharmacology - Wiley Online Library Wiley
Non-Hodgkin lymphoma survival rate: Outlook and more - Medical News Today
Non-Hodgkin lymphoma survival rate: Outlook and more Medical News Today
Low-grade B-cell non-Hodgkin lymphoma in the sternocleidomastoid muscle: a case report and review of literature - Frontiers
Low-grade B-cell non-Hodgkin lymphoma in the sternocleidomastoid muscle: a case report and review of literature Frontiers
Primary Pulmonary Non-Hodgkin Lymphoma: A Report of Two Cases and a Review of the Literature Emphasizing the Role of Radiotherapy - Cureus
Primary Pulmonary Non-Hodgkin Lymphoma: A Report of Two Cases and a Review of the Literature Emphasizing the Role of Radiotherapy Cureus
Non-Hodgkin's Lymphoma in Pregnancy: A Report of a Rare Case - Cureus
Non-Hodgkin's Lymphoma in Pregnancy: A Report of a Rare Case Cureus
Current treatment algorithm: diffuse large B cell lymphoma - Nature
Current treatment algorithm: diffuse large B cell lymphoma Nature